Steven G Chrysant

List of Publications by Year
in descending order

136	3,478	159585 30	168389 53
papers	citations	h-index	g-index

138	138	138	3114
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The debate over the optimal blood pressure treatment target of less than 130/80 mmHg. Postgraduate Medicine, 2023, 135, 208-213.	2.0	1
2	Relatability of Blood Pressure Monitoring With Wearable Cuffless Devices. American Journal of Cardiology, 2022, , .	1.6	3
3	Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective. Hospital Practice (1995), 2022, 50, 196-202.	1.0	5
4	Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors. Expert Review of Cardiovascular Therapy, 2022, 20, 223-232.	1.5	4
5	The pathophysiology and management of diuretic resistance in patients with heart failure. Hospital Practice (1995), 2021, , 1-9.	1.0	0
6	A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug. Expert Opinion on Drug Safety, 2021, 20, 635-640.	2.4	4
7	The Debate Over Egg Consumption and Incident Cardiovascular Disease. Cardiology in Review, 2021, 29, 238-244.	1.4	4
8	Adverse cardiovascular and blood pressure effects of drug-induced hypomagnesemia. Expert Opinion on Drug Safety, 2020, 19, 59-67.	2.4	6
9	New and emerging cardiovascular and antihypertensive drugs. Expert Opinion on Drug Safety, 2020, 19, 1315-1327.	2.4	5
10	The cardiometabolic benefits of exercise in postmenopausal women. Journal of Clinical Hypertension, 2020, 22, 1691-1693.	2.0	3
11	Orthostatic hypotension and cardiovascular outcomes: Should we be concerned?. Journal of Clinical Hypertension, 2020, 22, 2161-2162.	2.0	1
12	The current debate over treatment of subclinical hypothyroidism to prevent cardiovascular complications. International Journal of Clinical Practice, 2020, 74, e13499.	1.7	12
13	The clinical significance of isolated diastolic hypertension. Postgraduate Medicine, 2020, 132, 624-628.	2.0	11
14	Noninvasive vascular function tests for the future prediction of primary cardiovascular diseases. Hospital Practice (1995), 2020, 48, 113-118.	1.0	5
15	The tilt table test is useful for the diagnosis of vasovagal syncope and should not be abolished. Journal of Clinical Hypertension, 2020, 22, 686-689.	2.0	7
16	In response to: an opposing point of view on the obesity paradox. Postgraduate Medicine, 2019, 131, 388-389.	2.0	1
17	Obesity-related heart failure with preserved ejection fraction: new treatment strategies. Hospital Practice (1995), 2019, 47, 67-72.	1.0	7
18	New noninvasive vascular tests could improve the prediction and early diagnosis and treatment of cardiovascular diseases. Journal of Clinical Hypertension, 2019, 21, 893-895.	2.0	0

#	Article	IF	Citations
19	Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. Expert Review of Cardiovascular Therapy, 2019, 17, 345-351.	1.5	20
20	Association of hypomagnesemia with cardiovascular diseases and hypertension. International Journal of Cardiology: Hypertension, 2019, 1, 100005.	2.2	19
21	Pathophysiology and treatment of obesityâ€related hypertension. Journal of Clinical Hypertension, 2019, 21, 555-559.	2.0	33
22	The single use of body mass index for the obesity paradox is misleading and should be used in conjunction with other obesity indices. Postgraduate Medicine, 2019, 131, 96-102.	2.0	45
23	Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone. Hospital Practice (1995), 2018, 46, 47-55.	1.0	7
24	Obesity is bad regardless of the obesity paradox for hypertension and heart disease. Journal of Clinical Hypertension, 2018, 20, 842-846.	2.0	5
25	Aggressive systolic blood pressure control in older subjects: benefits and risks. Postgraduate Medicine, 2018, 130, 159-165.	2.0	17
26	Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension. Journal of Clinical Hypertension, 2018, 20, 351-355.	2.0	10
27	Authors reply: statins and new onset of diabetes: which one outweighs risk or benefit?. Postgraduate Medicine, 2018, 130, 147-147.	2.0	1
28	Sacubitril/valsartan: a cardiovascular drug with pluripotential actions. Cardiovascular Diagnosis and Therapy, 2018, 8, 543-548.	1.7	5
29	The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Expert Review of Cardiovascular Therapy, 2018, 16, 559-565.	1.5	117
30	The impact of coffee consumption on blood pressure, cardiovascular disease and diabetes mellitus. Expert Review of Cardiovascular Therapy, 2017, 15, 151-156.	1.5	32
31	New onset diabetes mellitus induced by statins: current evidence. Postgraduate Medicine, 2017, 129, 430-435.	2.0	37
32	New evidence for the diastolic Jâ€curve effect challenges theÂsafety of intensive blood pressure control. Journal of Clinical Hypertension, 2017, 19, 340-343.	2.0	8
33	Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. Journal of the American Society of Hypertension, 2017, 11, 461-468.	2.3	14
34	Herbs Used for the Treatment of Hypertension and their Mechanism of Action. Current Hypertension Reports, 2017, 19, 77.	3.5	36
35	Achieving blood pressure targets for prolonged cardiovascular health: a historical perspective. Expert Review of Cardiovascular Therapy, 2017, 15, 517-523.	1.5	3
36	Treatment of Modifiable Risk Factors Is Associated With Decrease in Coronary Heart Disease Incidence: Time to Use the Polypill. Journal of Clinical Hypertension, 2016, 18, 840-842.	2.0	3

#	Article	IF	Citations
37	Effects of High Salt Intake on Blood Pressure and Cardiovascular Disease: The Role of COX Inhibitors. Clinical Cardiology, 2016, 39, 240-242.	1.8	17
38	The Clinical Significance of Nâ€terminal Proâ€brain Natriuretic Peptide in Detecting the Residual Cardiovascular Risk in Hypertension and Other Clinical Conditions and in Predicting Future Cardiovascular Events. Journal of Clinical Hypertension, 2016, 18, 718-720.	2.0	5
39	Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension. Current Hypertension Reports, 2016, 18, 14.	3.5	8
40	A Healthy Lifestyle Could Reduce the Onset of First Heart Attack by 80%. Journal of Clinical Hypertension, 2015, 17, 168-171.	2.0	5
41	The Cardiovascular Consequences of Excess Sitting Time. Journal of Clinical Hypertension, 2015, 17, 528-531.	2.0	6
42	Antihypertensive therapy causes erectile dysfunction. Current Opinion in Cardiology, 2015, 30, 383-390.	1.8	55
43	Coffee Consumption and Cardiovascular Health. American Journal of Cardiology, 2015, 116, 818-821.	1.6	22
44	Association of Exposure to Bisphenol A and Incidence of Cardiovascular Disease and Hypertension. Journal of Clinical Hypertension, 2015, 17, 737-739.	2.0	6
45	Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls. Current Hypertension Reports, 2015, 17, 511.	3.5	5
46	Early and sustained blood pressure control is necessary for stroke prevention. Journal of Thoracic Disease, 2015, 7, 1070-3.	1.4	0
47	Controversy Regarding the Association of High Calcium Intake and Increased Risk for Cardiovascular Disease. Journal of Clinical Hypertension, 2014, 16, 545-550.	2.0	20
48	Treatment of Hypertension in Patients with Atherosclerotic Renal Artery Stenosis, Updated. Postgraduate Medicine, 2014, 126, 59-67.	2.0	20
49	The Ageâ€Related Hemodynamic Changes of Blood Pressure and Their Impact on the Incidence of Cardiovascular Disease and Stroke: New Evidence. Journal of Clinical Hypertension, 2014, 16, 87-90.	2.0	26
50	Future of Polypill Use for the Prevention of Cardiovascular Disease and Strokes. American Journal of Cardiology, 2014, 114, 641-645.	1.6	13
51	Treatment of hypertension in patients with renal artery stenosis due to fibromuscular dysplasia of the renal arteries. Cardiovascular Diagnosis and Therapy, 2014, 4, 36-43.	1.7	15
52	Effectiveness and Safety of Phosphodiesterase 5 Inhibitors in Patients with Cardiovascular Disease and Hypertension. Current Hypertension Reports, 2013, 15, 475-483.	3.5	50
53	New insights into the true nature of the obesity paradox and the lower cardiovascular risk. Journal of the American Society of Hypertension, 2013, 7, 85-94.	2.3	78
54	Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. Expert Review of Cardiovascular Therapy, 2013, 11, 1115-1124.	1.5	7

#	Article	IF	Citations
55	The Current Status of Angioplasty of Atherosclerotic Renal Artery Stenosis for the Treatment of Hypertension. Journal of Clinical Hypertension, 2013, 15, 694-698.	2.0	7
56	An Update on the Cardiovascular Pleiotropic Effects of Milk and Milk Products. Journal of Clinical Hypertension, 2013, 15, 503-510.	2.0	22
57	Treating blood pressure to prevent strokes: The age factor. World Journal of Cardiology, 2013, 5, 22.	1.5	6
58	Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. Journal of the American Society of Hypertension, 2012, 6, 132-141.	2.3	31
59	Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovascular Diabetology, 2012, 11, 134.	6.8	29
60	Blood Pressure Effects of High-Dose Amlodipine-Benazepril Combination in Black and White Hypertensive Patients Not Controlled on Monotherapy. Drugs in R and D, 2012, 12, 57-64.	2.2	0
61	Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension. American Journal of Cardiovascular Drugs, 2012, 12, 233-243.	2.2	22
62	Olmesartan Medoxomil-Based Antihypertensive Therapy Evaluated by Ambulatory Blood Pressure Monitoring. American Journal of Cardiovascular Drugs, 2012, 12, 375-389.	2.2	4
63	The Role of Angiotensin II Receptors in Stroke Protection. Current Hypertension Reports, 2012, 14, 202-208.	3.5	19
64	Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors. American Journal of Cardiology, 2012, 109, 1681-1685.	1.6	60
65	Longâ€Term Efficacy and Safety of Tripleâ€Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension. Journal of Clinical Hypertension, 2012, 14, 149-157.	2.0	19
66	The Pleiotropic Effects of Phosphodiesterase 5 Inhibitors on Function and Safety in Patients With Cardiovascular Disease and Hypertension. Journal of Clinical Hypertension, 2012, 14, 644-649.	2.0	28
67	24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy. Journal of Clinical Hypertension, 2011, 13, 873-880.	2.0	35
68	Current Status of Aggressive Blood Glucose and Blood Pressure Control in Diabetic Hypertensive Subjects. American Journal of Cardiology, 2011, 107, 1856-1861.	1.6	15
69	Review of the Safety and Efficacy of Linagliptin as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study. Postgraduate Medicine, 2011, 123, 183-186.	2.0	5
70	Single-Pill Triple-Combination Therapy: An Alternative to Multiple-Drug Treatment of Hypertension. Postgraduate Medicine, 2011, 123, 21-31.	2.0	19
71	The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade. Current Clinical Pharmacology, 2010, 5, 89-95.	0.6	26
72	Current Status of Dual Renin Angiotensin Aldosterone System Blockade for the Treatment of Cardiovascular Diseases. American Journal of Cardiology, 2010, 105, 849-852.	1.6	24

#	Article	IF	Citations
73	Effectiveness of Lowering Blood Pressure to Prevent Stroke Versus to Prevent Coronary Events. American Journal of Cardiology, 2010, 106, 825-829.	1.6	46
74	Current Evidence on the Hemodynamic and Blood Pressure Effects of Isometric Exercise in Normotensive and Hypertensive Persons. Journal of Clinical Hypertension, 2010, 12, 721-726.	2.0	33
75	The Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension. American Journal of Cardiovascular Drugs, 2010, 10, 315-320.	2.2	19
76	Safety and Tolerability of an Olmesartan Medoxomil-Based Regimen in Patients with Stage 1 Hypertension. Clinical Drug Investigation, 2010, 30, 473-482.	2.2	4
77	Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Current Medical Research and Opinion, 2010, 26, 2841-2849.	1.9	15
78	The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan. Drugs of Today, 2010, 46, 151.	1.1	7
79	Stopping the cardiovascular disease continuum: Focus on prevention. World Journal of Cardiology, 2010, 2, 43.	1.5	12
80	Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. Expert Review of Cardiovascular Therapy, 2009, 7, 887-895.	1.5	6
81	Efficacy and Safety of Longâ€Term Treatment With the Combination of Amlodipine Besylate and Olmesartan Medoxomil in Patients With Hypertension. Journal of Clinical Hypertension, 2009, 11, 475-482.	2.0	55
82	Combination Therapy with Olmesartan Medoxomil and Hydrochlorothiazide. American Journal of Cardiovascular Drugs, 2009, 9, 241-251.	2.2	7
83	Irbesartan/Hydrochlorothiazide for the Treatment of Isolated Systolic Hypertension:A Subgroup Analysis of the INCLUSIVE Trial. Journal of the National Medical Association, 2009, 101, 300-307.	0.8	8
84	Current and Future Status of Betaâ€blockers in the Treatment of Hypertension. Clinical Cardiology, 2008, 31, 249-252.	1.8	27
85	Proactive Compared With Passive Adverse Event Recognition: Calcium Channel Blockerâ€“Associated Edema. Journal of Clinical Hypertension, 2008, 10, 716-722.	2.0	31
86	Results of an Olmesartan Medoxomilâ€“Based Treatment Regimen in Hypertensive Patients. Journal of Clinical Hypertension, 2008, 10, 911-921.	2.0	25
87	Using Fixed-Dose Combination Therapies to Achieve Blood Pressure Goals. Clinical Drug Investigation, 2008, 28, 713-734.	2.2	61
88	The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clinical Therapeutics, 2008, 30, 587-604.	2.5	247
89	Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum. Clinical Therapeutics, 2008, 30, 2181-2190.	2.5	24
90	Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Current Medical Research and Opinion, 2008, 24, 1039-1047.	1.9	40

#	Article	IF	Citations
91	Aliskirenâ€“hydrochlorothiazide combination for the treatment of hypertension. Expert Review of Cardiovascular Therapy, 2008, 6, 305-314.	1.5	11
92	Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Pressure Monitoring, 2008, 13, 21-27.	0.8	28
93	Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: Focus on amlodipine/olmesartan combination. Drugs of Today, 2008, 44, 443.	1.1	4
94	The effects of highâ€dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Pressure, 2007, 16, 10-17.	1.5	14
95	Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of Hypertension, 2007, 25, 217-226.	0.5	256
96	The Pathophysiologic Role of the Brain Renin-Angiotensin System in Stroke Protection: Clinical Implications. Journal of Clinical Hypertension, 2007, 9, 454-459.	2.0	31
97	The Pleiotropic Effects of Angiotensin Receptor Blockers. Journal of Clinical Hypertension, 2006, 8, 261-268.	2.0	46
98	Niacin-ER/Statin Combination for the Treatment of Dyslipidemia: Focus on Low High-Density Lipoprotein Cholesterol. Journal of Clinical Hypertension, 2006, 8, 493-501.	2.0	9
99	Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Pressure Monitoring, 2006, 11, 135-141.	0.8	21
100	Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases. Current Clinical Pharmacology, 2006, 1, 139-146.	0.6	7
101	Telmisartan/Hydrochlorothiazide in Comparison with Losartan/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate Hypertension. Hypertension Research, 2005, 28, 555-563.	2.7	49
102	Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opinion on Pharmacotherapy, 2004, 5, 657-667.	1.8	21
103	Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. American Journal of Hypertension, 2004, 17, 252-259.	2.0	133
104	Combination therapy with an ace-inhibitor (acei)/calcium channel blocker (ccb) for hypertensive patients non-responsive to ace-inhibitor monotherapy: an efficacy and safety trial. American Journal of Hypertension, 2004, 17, S102.	2.0	0
105	Olmesartan medoxomil lowers blood pressure as rapidly as amlodipine besylate in patients with mild to moderate hypertension: results of a randomized, double-blind, placebo-controlled study. American Journal of Hypertension, 2004, 17, S102.	2.0	0
106	Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. American Journal of Hypertension, 2004, 17, 590-596.	2.0	23
107	Pharmacological and Clinical Profile of Moexipril: A Concise Review. Journal of Clinical Pharmacology, 2004, 44, 827-836.	2.0	9
108	Clinical Experience With Angiotensin Receptor Blockers With Particular Reference to Valsartan. Journal of Clinical Hypertension, 2004, 6, 445-451.	2.0	14

#	Article	IF	Citations
109	Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs of Today, 2004, 40, 791.	2.4	18
110	Has the role of calcium channel blockers in treating hypertension finally been defined?. Current Hypertension Reports, 2003, 5, 295-300.	3.5	2
111	Pharmacological profile and clinical use of moexipril. Expert Review of Cardiovascular Therapy, 2003, 1, 345-352.	1.5	3
112	Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (DiovanÂ®/HCT). Expert Review of Cardiovascular Therapy, 2003, 1, 335-343.	1.5	25
113	Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension. Journal of Clinical Hypertension, 2001, 3, 283-318.	2.0	233
114	Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. American Journal of Cardiology, 2001, 87, 727-731.	1.6	53
115	Treatment of white coat hypertension. Current Hypertension Reports, 2000, 2, 412-417.	3.5	24
116	Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. Current Therapeutic Research, 1998, 59, 762-772.	1.2	16
117	Vascular remodeling: The role of angiotensin-converting enzyme inhibitors. American Heart Journal, 1998, 135, S21-S30.	2.7	82
118	Antihypertensive Effectiveness of a Very Low Fixed-Dose Combination of Moexipril and Hydrochlorothiazide. Journal of Cardiovascular Pharmacology, 1998, 31, 384-390.	1.9	16
119	Perindopril/Hydrochlorothiazide Dose Combinations for the Treatment of Hypertension: A Multicenter Study. Journal of Clinical Pharmacology, 1997, 37, 47-52.	2.0	13
120	Clinical Utility of Longâ€Term Enalapril/Diltiazem ER in Stage 3â€“4 Essential Hypertension. Journal of Clinical Pharmacology, 1997, 37, 810-815.	2.0	9
121	Antihypertensive effects of mibefradil: A doubleâ€blind comparison with diltiazem CD. Clinical Cardiology, 1997, 20, 562-568.	1.8	14
122	Sustained Blood Pressure Control with Controlledâ€Release Isradipine (Isradipineâ€CR). Journal of Clinical Pharmacology, 1995, 35, 239-243.	2.0	7
123	Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Parallelâ€Group Study. Journal of Clinical Pharmacology, 1995, 35, 1060-1066.	2.0	82
124	Antihypertensive Effectiveness of Low-Dose Lisinopril-Hydrochlorothiazide Combination. Archives of Internal Medicine, 1994, 154, 737.	3.8	64
125	Effects of atenolol and diltiazemâ€SR on exercise and pressure load in hypertensive patients. Clinical Cardiology, 1994, 17, 670-674.	1.8	6
126	Perindopril as monotherapy in hypertension: A multicenter comparison of two dosing regimens. Clinical Pharmacology and Therapeutics, 1993, 53, 479-484.	4.7	23

#	Article	IF	Citations
127	Antihypertensive and Metabolic Effects of Single and Combined Atenolol Regimens. Journal of Clinical Pharmacology, 1992, 32, 61-65.	2.0	23
128	Treatment of Severe Hypertension with Atenolol and Betaxolol with Once-Daily Regimens. Chest, 1989, 96, 499-504.	0.8	10
129	Antihypertensive Effectiveness of Amlodipine in Combination With Hydrochlorothiazide. American Journal of Hypertension, 1989, 2, 537-541.	2.0	32
130	Hemodynamic and Metabolic Effects of Hypomagnesemia in Spontaneously Hypertensive Rats. Cardiology, 1988, 75, 81-89.	1.4	25
131	Severe Reversible Azotemia From Captopril Therapy. Archives of Internal Medicine, 1983, 143, 437.	3.8	45
132	Effects of Diet on Exaggerated Natriuresis in Hypertension. Clinical and Experimental Hypertension, 1981, 3, 55-68.	1.3	2
133	Effects of Amiloride on Arterial Pressure and Renal Function. Journal of Clinical Pharmacology, 1980, 20, 332-337.	2.0	10
134	Renal Functional and Organic Changes Induced by Salt and Prostaglandin Inhibition in Spontaneously Hypertensive Rats. Nephron, 1980, 25, 151-155.	1.8	7
135	Abrupt cessation of clonidine administration: A prospective study. American Journal of Cardiology, 1978, 41, 1285-1290.	1.6	60
136	Hemodynamic Effects of Isometric Exercise in Normotensive Hypertensive Subjects Hypertension. Angiology, 1978, 29, 379-385.	1.8	11